2. Academic Validation
  3. Quercetin alleviates hyperoxia-induced bronchopulmonary dysplasia by inhibiting ferroptosis through the MAPK/PTGS2 pathway: Insights from network pharmacology, molecular docking, and experimental evaluations

Quercetin alleviates hyperoxia-induced bronchopulmonary dysplasia by inhibiting ferroptosis through the MAPK/PTGS2 pathway: Insights from network pharmacology, molecular docking, and experimental evaluations

  • Chem Biol Drug Des. 2024 Apr;103(4):e14520. doi: 10.1111/cbdd.14520.
Xianhui Deng 1,  Dan Chen 2,  Anni Xie 1,  Shengpeng Li 2,  Ailing Chen 3,  Qin Zhou 1 4,  Renqiang Yu 1 3
Affiliations

Affiliations

  • 1 Department of Neonatology, Affiliated Women's Hospital of Jiangnan University, Wuxi Maternity and Child Health Care Hospital, Wuxi, China.
  • 2 Department of Physiopathology, Wuxi School of Medicine, Jiangnan University, Wuxi, China.
  • 3 Research Institute for Reproductive Health and Genetic Diseases, Affiliated Women's Hospital of Jiangnan University, Wuxi, China.
  • 4 Department of Pediatric, Wuxi Yihe Gynaecology and Obstetrics Hospital, Wuxi, China.
PMID: 38570710 DOI: 10.1111/cbdd.14520
Abstract

Quercetin, a bioactive natural compound renowned for its potent anti-inflammatory, antioxidant, and Antiviral properties, has exhibited therapeutic potential in various diseases. Given that bronchopulmonary dysplasia (BPD) development is closely linked to inflammation and oxidative stress, and quercetin, a robust antioxidant known to activate NRF2 and influence the Ferroptosis pathway, offers promise for a wide range of age groups. Nonetheless, the specific role of quercetin in BPD remains largely unexplored. This study aims to uncover the target role of quercetin in BPD through a combination of network pharmacology, molecular docking, computer analyses, and experimental evaluations.

Keywords

PTGS2; bronchopulmonary dysplasia; ferroptosis; hyperoxia; quercetin.

Figures
Products